FHTX

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing medicines targeting genetically determined dependencies within the chromatin regulatory system. The company's proprietary Gene Traffic Control platform identifies and validates novel drug targets within chromatin regulatory mechanisms. Foghorn's pipeline includes oncology programs aimed at treating cancers with specific genetic alterations. The company collaborates with leading academic institutions and maintains strategic partnerships to advance its therapeutic candidates. Foghorn focuses on precision medicine approaches where patient selection is guided by genetic biomarkers. The firm is based in Cambridge, Massachusetts, within the biotech cluster.